Conditional relative survival among patients with chronic lymphocytic leukaemia: A population‐based study in the Netherlands
Lina van derStraten,
Mark‐David Levin,
Otto Visser,
Eduardus F.M. Posthuma,
Jeanette K. Doorduijn,
Arnon P. Kater,
Avinash G. Dinmohamed
Affiliations
Lina van derStraten
Department of Research and Development Netherlands Comprehensive Cancer Organisation (IKNL) Utrecht The Netherlands
Mark‐David Levin
Department of Internal Medicine Albert Schweitzer Hospital Dordrecht The Netherlands
Otto Visser
Department of Registration Netherlands Comprehensive Cancer Organisation (IKNL) Utrecht The Netherlands
Eduardus F.M. Posthuma
Department of Internal Medicine Reinier The Graaf Hospital Delft The Netherlands
Jeanette K. Doorduijn
Erasmus MC Cancer Institute, Department of Hematology University Medical Center Rotterdam Rotterdam The Netherlands
Arnon P. Kater
Amsterdam UMC, University of Amsterdam, Department of Hematology Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam Amsterdam The Netherlands
Avinash G. Dinmohamed
Department of Research and Development Netherlands Comprehensive Cancer Organisation (IKNL) Utrecht The Netherlands
Abstract Studies on conditional relative survival (CRS) in chronic lymphocytic leukaemia (CLL) have hitherto been lacking in the literature. We predicted up‐to‐date estimates of 5‐year RS at diagnosis and for each additional year survived (i.e., CRS) up to 15 years post‐diagnosis among CLL patients diagnosed during 2007–2020. We showed that 5‐year CRS continues to decline gradually with each additional year survived in a contemporary era with access to novel‐based agents, irrespective of age. This finding indicates that CLL patients continue to experience substantial excess mortality compared to an age‐ and sex‐matched group from the general population.
